18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. We will assess the uptake of this novel radiopharmaceutical in subjects with breast cancer, lung cancer, glioblastoma multiforme (GBM) and other cancers requiring antiangiogenesis treatment.

Principal Investigator

  • Sanjiv Sam Gambhir, MD, PhD

Stanford Investigator(s)

  • Melinda L. Telli, M.D.
  • Heather Wakelee
  • Lawrence Recht, MD
  • Erik Mittra
  • Andrei Iagaru


Primary Contact:
(650) 498-7061